$OREX (Orexigen Therapeutics, Inc.)

$OREX {{ '2015-08-06T13:40:23+0000' | timeago}} • Webcast

$OREX 2Q15 Q&A: Ryan of JP Morgan asked to talk about where company is in discussions regarding the partnership opportunity. Mike answered that resolution of dispute with Takeda, establishment of Irish subsidiary discussions are advancing. Company does have dialogs ongoing with interested parties.

$ZLTQ {{ '2016-04-26T20:04:51+0000' | timeago}} • Announcement

$ZLTQ said David Endicott has joined its BoD. Mr. Endicott currently serves on $OREX's BoD and as a member of the BoD for AdvaMed, the principal industry association for medical devices. Concurrent with Mr. Endicott's appointment, Dr. Bryan Roberts advised $ZLTQ that he will not be standing for reelection to the BoD at the upcoming annual meeting.

$OREX {{ '2015-12-08T21:04:19+0000' | timeago}} • SEC

$OREX's wholly owned subsidiary Orexigen Therapeutics Ireland, Ltd. entered into a distributorship agreement for Contrave with Korea-based company Kwang Dong Pharmaceutical Company, Ltd. Kwang Dong expects to begin marketing Contrave in 2H16. For the nine months ended Sept. 30, 2015, $OREX recognized revenues under this agreement of $61,000.

$OREX {{ '2015-12-08T21:03:12+0000' | timeago}} • SEC

In Sept. 2015, $OREX sold 20MM shares of its common stock & warrants to purchase 5MM shares of its common stock in a private placement to an affiliate of The Baupost Group LLC at a purchase price of $3.00 per share of common stock and 0.25 of a warrant, raising net proceeds of $59.8MM. The warrants are exercisable for five years at $6.00 per share.

$OREX {{ '2015-12-08T21:01:42+0000' | timeago}} • SEC

$OREX generated approx. $19.5MM in revenue for the nine months ended Sept. 30, 2015, primarily resulting from the sublicensing of technology and amounts earned under the collaboration agreement between $OREX and Takeda Pharmaceutical Company Limited.

$OREX {{ '2015-11-05T23:14:50+0000' | timeago}} • Webcast

As of Sept. 30, 2015, $OREX had $154.3MM in cash and cash equivalents and an additional $79.2MM in marketable securities, for a total of $233.4MM.

$OREX {{ '2015-11-05T23:02:19+0000' | timeago}} • Webcast

$OREX expects total operating expense for FY15 to be between $90-100MM and end the year with a balance of cash and investments exceeding $200MM indicating estimated cash burn from operations in 2015 of approx. $60-65MM.

$OREX {{ '2015-11-05T22:52:14+0000' | timeago}} • Webcast

During 3Q15, $OREX received a total of $22MM in milestone payments for its obesity drug Contrave from its partners, which includes $15MM from Takeda Pharmaceutical Company and $7MM from Kwang Dong Pharmaceutical Company.

$OREX {{ '2015-11-05T22:19:39+0000' | timeago}} • Announcement

In September, $OREX received the first of three potential $15MM anniversary milestone payments from Takeda Pharmaceuticals, $OREX's North American partner for Contrave drug. Two additional potential $15MM payments are expected from Takeda in 4Q16 and 4Q17.

$OREX {{ '2015-11-05T22:14:08+0000' | timeago}} • Announcement

Obesity drug developer $OREX's revenue tumbled to $10MM from $30.8MM in 3Q14. The reported revenue for the quarter includes $2.6MM in royalties earned on U.S. net sales of Contrave of $12.8MM recorded by $OREX's partner Takeda Pharmaceuticals.

$OREX {{ '2015-11-05T21:59:59+0000' | timeago}} • Announcement

Biopharmaceutical company $OREX reported a net loss of $11.1MM, or $0.09 per share, in 3Q15 as compared to a net income of $11.3MM, or $0.09 per share in 3Q14.

$OREX {{ '2015-11-05T21:48:43+0000' | timeago}} • Announcement

$OREX's total operating expenses for 3Q15 were $20.9MM compared to $17.8MM of prior-year quarter, driven by an increase in general and administrative expense, primarily for marketing and consulting costs.

$OREX {{ '2015-08-06T13:50:01+0000' | timeago}} • Webcast

$OREX 2Q15 Q&A: Simeonidis of RBC Capital asked in terms of potential lifecycle management for Contrave, who pays for it now. Mike answered that Takeda & OREX are discussing lifecycle opportunities, whether formal studies to amend label or other studies. The studies will be shared by both parties, 75% Takeda, 25% OREX. OREX might fund the studies.

$OREX {{ '2015-08-06T13:44:35+0000' | timeago}} • Webcast

$OREX 2Q15 Q&A: Andrews of Wells Fargo asked to generally talk about what extend Takeda may want to be more aggressively contracting to try to get some exclusivity on Tier 2. Tom answered that all health plans seem to be inclined to have more of an open-access formulary and put products in Tier 3. That's the natural start for negotiation.

$OREX {{ '2015-08-06T13:40:23+0000' | timeago}} • Webcast

$OREX 2Q15 Q&A: Ryan of JP Morgan asked to talk about where company is in discussions regarding the partnership opportunity. Mike answered that resolution of dispute with Takeda, establishment of Irish subsidiary discussions are advancing. Company does have dialogs ongoing with interested parties.

$OREX {{ '2015-08-06T13:26:07+0000' | timeago}} • Webcast

$OREX 2Q15 Q&A: Duncan of Piper Jaffray asked to give color on the driver to superior prescription performances. Tom answered it is good solid growth of overall market and branded market coupled with good, steady share penetration which is really driven by differentiated product profile. Strong pricing program and patient support program.

$OREX {{ '2015-08-06T13:21:41+0000' | timeago}} • Webcast

$OREX 2Q15 Q&A: Matteis of Leerink asked about updated planning with Takeda on potential diabetes study or investing in other promotional efforts. Mike answered that one is to follow lifecycle promotional commitments, how exactly company will allocate committed resources over time. Wants to focus resource allocation on what can drive most value.

$OREX {{ '2015-08-06T13:14:52+0000' | timeago}} • Webcast

$OREX 2Q15 Q&A: Matteis of Leerink asked about promotion of 900 reps, how much longer are they committed to put force to that amount of resources. Joseph answered that OREX has multi-year contractually obligated minimum commitments to promotional levels, marketing spend and incentive compensation from the field force. Details will not be disclosed.

$OREX {{ '2015-08-06T13:08:05+0000' | timeago}} • Webcast

$OREX 2Q15 Call: In June, Contrave grew to 34.3% share of the branded market vs. $32.9% in May and now is also the growing lead over the other agents. Contrave had strong Rx volume for June, 61,000 prescriptions according to IMS Health, which was up 8% vs. May performance and in 2Q15, total prescription volume was 172,000, up 47% over 1Q15.

$OREX {{ '2015-08-06T12:59:49+0000' | timeago}} • Webcast

$OREX 2Q15 Call: In 1H15, overall market was up 14% vs. 1H14. Now, overall market grew about 10% for 2014 vs. 2013. Branded market, including Xenical, Qsymia, Belviq, Contrave and Saxenda, was up about 101% for 1H15 vs. 1H14. In the long term, market has very strong potential given the low treatment penetration rates in huge unmet needs.

$OREX {{ '2015-08-06T12:49:13+0000' | timeago}} • Webcast

$OREX 2Q15 Call: Estimates that third-party costs that OREX will bear for US & EU post-marketing obligations will be approx. $20-25MM in remainder of 2015 & approx. $35-45MM for each of 2016 & 2017. Through 2017, OREX is eligible to receive $45MM in anniversary milestones that are not included in current guidance & that helps offset cash expense.

Recent Transcripts

ONVO (Organovo Holdings, Inc.)
Wednesday, June 7 2017 - 9:00pm
PTN (Palatin Technologies Inc.)
Tuesday, May 16 2017 - 3:00pm
TEVA (Teva Pharmaceutical Industries Limited)
Thursday, May 11 2017 - 12:00pm
ACAD (ACADIA Pharmaceuticals Inc.)
Tuesday, May 9 2017 - 9:00pm
OREX (Orexigen Therapeutics, Inc.)
Tuesday, May 9 2017 - 9:00pm
ARNA (Arena Pharmaceuticals Inc)
Tuesday, May 9 2017 - 8:30pm
VRX (Valeant Pharmaceuticals International, Inc.)
Tuesday, May 9 2017 - 12:00pm
SYN (Synthetic Biologics Inc.)
Thursday, May 4 2017 - 8:30pm
ZTS (Zoetis Inc.)
Thursday, May 4 2017 - 12:30pm
NVO (Novo Nordisk A/S)
Thursday, May 4 2017 - 12:15pm
VVUS (VIVUS Inc.)
Wednesday, May 3 2017 - 8:30pm
NVO (Novo Nordisk A/S)
Wednesday, May 3 2017 - 11:00am
AZN (AstraZeneca PLC)
Thursday, April 27 2017 - 11:00am
GSK (GlaxoSmithKline plc)
Wednesday, April 26 2017 - 1:00pm
OREX (Orexigen Therapeutics, Inc.)
Tuesday, March 28 2017 - 9:00pm
ARNA (Arena Pharmaceuticals Inc)
Tuesday, March 14 2017 - 8:30pm
VVUS (VIVUS Inc.)
Wednesday, March 8 2017 - 9:30pm
SYN (Synthetic Biologics Inc.)
Thursday, March 2 2017 - 9:30pm
ACAD (ACADIA Pharmaceuticals Inc.)
Tuesday, February 28 2017 - 10:00pm
VRX (Valeant Pharmaceuticals International, Inc.)
Tuesday, February 28 2017 - 1:00pm

AlphaGraphics you may like